中藥材基原跨國藥典速查|Chinese Herbal Medicine Pharmacopoeia Comparison
本工具以《臺灣中藥典》第四版(Taiwan Herbal Pharmacopoeia IV,THP IV)355 種藥材為索引骨架,逐項比對《中華人民共和國藥典》2025 年版(Chinese Pharmacopoeia 2025,ChP 2025)、《日本藥局方》第十八改正(Japanese Pharmacopoeia 18,JP XVIII)及《日本藥局方外生藥規格》2022(Japanese Standards for Non-Pharmacopoeial Crude Drugs,局外生規)、《大韓民國藥典》第十二改正(Korean Pharmacopoeia XII,KP XII)與《大韓民國藥典外韓藥(生藥)規格集》(Korean Herbal Pharmacopoeia,KHP)、《越南藥典》第五版(Vietnamese Pharmacopoeia V,VP V)、《印度阿育吠陀藥典》(The Ayurvedic Pharmacopoeia of India,API)、《歐洲藥典》第十一版(European Pharmacopoeia 11,Ph.Eur. 11)、世界衛生組織藥用植物專論(WHO Monographs on Selected Medicinal Plants,WHO)、《印尼草藥典》第二版(Farmakope Herbal Indonesia II,FHI II)之收載、學名(經 POWO+COL+GBIF 核校)、藥用部位與含量規範。支援中英雙語、指標成分反查與 CSV 匯出。
A cross-pharmacopoeia comparison of 355 Chinese herbal medicines (materia medica / crude drugs) across nine pharmacopoeias — the Taiwan Herbal Pharmacopoeia IV (THP IV), Chinese Pharmacopoeia 2025 (ChP 2025), Japanese Pharmacopoeia 18 (JP XVIII) and Non-Pharmacopoeial Crude Drug Standards (Non-JPS), Korean Pharmacopoeia XII (KP XII) and Korean Herbal Pharmacopoeia (KHP), Vietnamese Pharmacopoeia V (VP V), the Ayurvedic Pharmacopoeia of India (API), the European Pharmacopoeia 11 (Ph.Eur. 11), WHO Monographs on Selected Medicinal Plants (WHO) and the Indonesian Herbal Pharmacopoeia II (FHI II) — covering collection status, scientific name / source species (verified against POWO, Catalogue of Life and GBIF), medicinal part and assay specifications. A reference for TCM (traditional Chinese medicine) researchers, pharmacists and herbalists.
本頁需啟用 JavaScript 以載入完整比對表。This page requires JavaScript to load the full comparison table.